{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:57:27Z","timestamp":1789466247310,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04499-9","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T05:00:28Z","timestamp":1669870828000},"page":"5429-5436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors"],"prefix":"10.1007","volume":"149","author":[{"given":"Austin R.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi T.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"2","key":"4499_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo M et al (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121\u2013130","journal-title":"Ann Intern Med"},{"issue":"30","key":"4499_CR2","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1200\/JCO.19.00320","volume":"37","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali F, Naqash A et al (2019) Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 37(30):2738\u20132745","journal-title":"J Clin Oncol"},{"issue":"6","key":"4499_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.19.01674","volume":"38","author":"H Abu-Sbeih","year":"2020","unstructured":"Abu-Sbeih H, Faleck D, Ricciuti B et al (2020) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 38(6):576\u2013583","journal-title":"J Clin Oncol"},{"issue":"15","key":"4499_CR4","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1200\/JCO.2021.39.15_suppl.2642","volume":"39","author":"H Abu-Sbeih","year":"2021","unstructured":"Abu-Sbeih H, Zou F, Dutra B et al (2021) Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis. J Clin Oncol 39(15):2642","journal-title":"J Clin Oncol"},{"issue":"4","key":"4499_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/ajg.2018.8","volume":"113","author":"M Ahmed","year":"2018","unstructured":"Ahmed M, Francis G (2018) Pembrolizumab-induced microscopic colitis. Am J Gastroenterol 113(4):629\u2013630","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"4499_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1136\/gut.37.3.394","volume":"37","author":"J Bohr","year":"1995","unstructured":"Bohr J, Tysk C, Eriksson S et al (1995) Collagenous colitis in Orebro, Sweden, an epidemiological study 1984\u20131993. Gut 37(3):394\u2013397","journal-title":"Gut"},{"issue":"6","key":"4499_CR7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368\u20131379","journal-title":"Ann Oncol"},{"issue":"2","key":"4499_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ibd\/izy240","volume":"25","author":"K Choi","year":"2019","unstructured":"Choi K, Abu-Sbeih H, Samdani R et al (2019) Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 25(2):385\u2013393","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"4499_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00004836-200203000-00008","volume":"34","author":"M Cindoruk","year":"2002","unstructured":"Cindoruk M, Tuncer C, Dursun A et al (2002) Increased colonic intraepithelial lymphocytes in patients with Hashimoto\u2019s thyroiditis. J Clin Gastroenterol 34(3):237\u2013239","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"4499_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11894-017-0551-3","volume":"19","author":"T Cotter","year":"2017","unstructured":"Cotter T, Pardi D (2017) Current approach to the evaluation and management of microscopic colitis. Curr Gastroenterol Rep 19(2):8","journal-title":"Curr Gastroenterol Rep"},{"issue":"9","key":"4499_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1200\/JOP.19.00672","volume":"16","author":"S Grover","year":"2020","unstructured":"Grover S, Ruan A, Srivoleti P et al (2020) Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract 16(9):933\u2013942","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"4499_CR12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3748\/wjg.v23.i7.1319","volume":"23","author":"S G\u00fcnaltay","year":"2017","unstructured":"G\u00fcnaltay S, Rademacher L, H\u00f6rnquist E et al (2017) Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol 23(7):1319\u20131324","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4499_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/ajco.12651","volume":"13","author":"N Hillock","year":"2017","unstructured":"Hillock N, Heard S, Kichenadasse G et al (2017) Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia Pac J Clin Oncol 13(5):284\u2013290","journal-title":"Asia Pac J Clin Oncol"},{"issue":"12","key":"4499_CR14","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1080\/00365521.2020.1839544","volume":"55","author":"S Holster","year":"2020","unstructured":"Holster S, Rode J, Bohr J et al (2020) Faecal microbiota transfer in patients with microscopic colitis - a pilot study in collagenous colitis. Scand J Gastroenterol 55(12):1454\u20131466","journal-title":"Scand J Gastroenterol"},{"issue":"28","key":"4499_CR15","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193\u20133198","journal-title":"J Clin Oncol"},{"issue":"43","key":"4499_CR16","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.3748\/wjg.v18.i43.6206","volume":"18","author":"G Ianiro","year":"2012","unstructured":"Ianiro G, Cammarota G, Valerio L et al (2012) Microscopic colitis. World J Gastroenterol 18(43):6206\u20136215","journal-title":"World J Gastroenterol"},{"issue":"26","key":"4499_CR17","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.3748\/wjg.v19.i26.4252","volume":"19","author":"R Jegadeesan","year":"2013","unstructured":"Jegadeesan R, Liu X, Pagadala M et al (2013) Microscopic colitis: is it a spectrum of inflammatory bowel disease? World J Gastroenterol 19(26):4252\u20134256","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4499_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"D Johnson","year":"2016","unstructured":"Johnson D, Sullivan R, Ott P et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234\u2013240","journal-title":"JAMA Oncol"},{"issue":"3","key":"4499_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00004836-200103000-00009","volume":"32","author":"C Matteoni","year":"2001","unstructured":"Matteoni C, Goldblum J, Wang N et al (2001) Celiac disease is highly prevalent in lymphocytic colitis. J Clin Gastroenterol 32(3):225\u2013227","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"4499_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"A Menzies","year":"2017","unstructured":"Menzies A, Johnson D, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368\u2013376","journal-title":"Ann Oncol"},{"key":"4499_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"J Michot","year":"2016","unstructured":"Michot J, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"4499_CR22","doi-asserted-by":"crossref","unstructured":"Nielsen D, Juhl C, Chen I, et al. Immune checkpoint inhibitor-induced diarrhea and colitis: dncidence and management. A systematic review and meta-analysis. Cancer Treat Rev. 2022;109:102440.","DOI":"10.1016\/j.ctrv.2022.102440"},{"issue":"1","key":"4499_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ajg.2016.477","volume":"112","author":"D Pardi","year":"2017","unstructured":"Pardi D (2017) Diagnosis and management of microscopic colitis. Am J Gastroenterol 112(1):78\u201385","journal-title":"Am J Gastroenterol"},{"issue":"29","key":"4499_CR24","doi-asserted-by":"publisher","first-page":"8804","DOI":"10.3748\/wjg.v21.i29.8804","volume":"21","author":"T Park","year":"2015","unstructured":"Park T, Cave D, Marshall C (2015a) Microscopic colitis: a review of etiology, treatment and refractory disease. World J Gastroenterol 21(29):8804\u20138810","journal-title":"World J Gastroenterol"},{"issue":"3","key":"4499_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5009\/gnl13439","volume":"9","author":"EK Park","year":"2015","unstructured":"Park EK, Park YS, Park DR et al (2015b) Cytokine expression of microscopic colitis including interleukin-17. Gut Liver 9(3):381\u2013387","journal-title":"Gut Liver"},{"key":"4499_CR26","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long G (2015) Pembrolizumab versus ipilimumab in advanced melanoma. NEJM 372:2521\u20132532","journal-title":"NEJM"},{"issue":"4","key":"4499_CR27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui B, Anandhan S et al (2021) The next decade of immune checkpoint therapy. Cancer Discov 11(4):838\u2013857","journal-title":"Cancer Discov"},{"key":"4499_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/352718","volume":"2013","author":"M Storr","year":"2013","unstructured":"Storr M (2013) Microscopic colitis: epidemiology, pathophysiology, diagnosis and current management-an update 2013. ISRN Gastroenterol 2013:352718","journal-title":"ISRN Gastroenterol"},{"issue":"4","key":"4499_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/jcp.2005.036376","volume":"60","author":"P Tagkalidis","year":"2007","unstructured":"Tagkalidis P, Gibson P, Bhathal P (2007) Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol 60(4):382\u2013387","journal-title":"J Clin Pathol"},{"key":"4499_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","volume":"12","author":"L Tang","year":"2021","unstructured":"Tang L, Wang J, Lin N et al (2021) Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 12:800879","journal-title":"Front Immunol"},{"key":"4499_CR31","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf [accessed on 4 March 2022]."},{"issue":"12","key":"4499_CR32","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wiesnoski D, Helmink B et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804\u20131808","journal-title":"Nat Med"},{"issue":"4","key":"4499_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/00365521.2018.1430252","volume":"53","author":"A Wickbom","year":"2018","unstructured":"Wickbom A, Bohr J, Nyhlin N et al (2018) Microscopic colitis in patients with ulcerative colitis or Crohn\u2019s disease: a retrospective observational study and review of the literature. Scand J Gastroenterol 53(4):410\u2013416","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"4499_CR34","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wynat","year":"2016","unstructured":"Wynat T, Fedyk E, Abhyanker B (2016) An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 10(12):1437\u20131444","journal-title":"J Crohns Colitis"},{"issue":"6","key":"4499_CR35","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/emp2.12209","volume":"1","author":"S Yeung","year":"2020","unstructured":"Yeung S, Odaisat A, Chaftari P et al (2020) Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open 1(6):1637\u20131659","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"6","key":"4499_CR36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.6004\/jnccn.2020.7647","volume":"19","author":"F Zou","year":"2020","unstructured":"Zou F, Abu-Sbeih H, Ma W et al (2020) Association of chronic immune-mediated diarrhea and colitis with favorable cancer response. J Natl Compr Canc Netw 19(6):700\u2013708","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"4499_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003277","volume":"9","author":"F Zou","year":"2021","unstructured":"Zou F, Faleck D, Thomas A et al (2021) Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11):e003277","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04499-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04499-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04499-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:21:10Z","timestamp":1689430870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04499-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4499"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04499-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"4 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None of the authors have competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval for this study was granted by the Institutional Review Board of the University of Texas MD Anderson Cancer Center (PA18-0472). Patient consent was waived for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}